Differential effects of N-acetyl-aspartyl-glutamate on synaptic and extrasynaptic NMDA receptors are subunit- and pH-dependent in the CA1 region of the mouse hippocampus

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 580-592

  Khacho, Pamela ^a   Wang, Boyang ^a   Ahlskog, Nina ^a   Hristova, Elitza ^a   Bergeron, Richard ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

2 PMPA; Biotinylation; Electrophysiology; Hippocampus; N acetyl aspartyl glutamate (NAAG); Neuroprotection; NMDA receptors; Protons

Indexed keywords

N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; DIPEPTIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-ACETYL-1-ASPARTYLGLUTAMIC ACID; PROTON;

ADULT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; HIPPOCAMPAL CA1 REGION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; UPREGULATION; ANIMAL; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; SYNAPSE; TISSUE CULTURE TECHNIQUE;

ANIMALS; CA1 REGION, HIPPOCAMPAL; DIPEPTIDES; EXCITATORY POSTSYNAPTIC POTENTIALS; HEK293 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; PATCH-CLAMP TECHNIQUES; PROTONS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES; TISSUE CULTURE TECHNIQUES;

EID: 84946496901     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.08.017     Document Type: Article

References (86)

1. Banke T.G., Dravid S.M., Traynelis S.F. Protons trap NR1/NR2B NMDA receptors in a nonconducting state. J. Neurosci. 2005, 25:42-51.
2. Bellone C., Nicoll R.A. Rapid bidirectional switching of synaptic NMDA receptors. Neuron 2007, 55:779-785.
3. Bergeron R., Coyle J.T. NAAG, NMDA receptor and psychosis. Curr. Med. Chem. 2012, 19:1360-1364.
4. Bergeron R., Coyle J.T., Tsai G., Greene R.W. NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 2005, 30:7-16.
5. Bergeron R., Imamura Y., Frangioni J.V., Greene R.W., Coyle J.T. Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. J. Neurochem. 2007, 100:346-357.
6. Cai Z., Lin S., Rhodes P.G. Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia. Eur. J. Pharmacol. 2002, 437:139-145.
7. Carpenter-Hyland E.P., Woodward J.J., Chandler L.J. Chronic ethanol induces synaptic but not extrasynaptic targeting of NMDA receptors. J. Neurosci. 2004, 24:7859-7868.
8. Casey J.R., Grinstein S., Orlowski J. Sensors and regulators of intracellular pH. Nat. Rev. Mol. Cell Biol. 2010, 11:50-61.
9. Chang H.R., Kuo C.C. The activation gate and gating mechanism of the NMDA receptor. J. Neurosci. 2008, 28:1546-1556.
10. 2+ inhibition of the NMDA receptor. Neuron 1999, 23:171-180.
11. Clements J.D., Lester R.A., Tong G., Jahr C.E., Westbrook G.L. The time course of glutamate in the synaptic cleft. Science 1992, 258:1498-1501.
12. Cull-Candy S., Brickley S., Farrant M. NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 2001, 11:327-335.
13. + conductances contribute to resting membrane potential and to orexin-induced membrane depolarization in rat thalamic paraventricular nucleus neurons. Neuroscience 2009, 158:1560-1570.
14. Doyle K.P., Simon R.P., Stenzel-Poore M.P. Mechanisms of ischemic brain damage. Neuropharmacology 2008, 55:310-318.
15. Dravid S.M., Erreger K., Yuan H., Nicholson K., Le P., Lyuboslavsky P., Almonte A., Murray E., Mosely C., Barber J., French A., Balster R., Murray T.F., Traynelis S.F. Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J. Physiol. 2007, 581:107-128.
16. Fellman V., Raivio K.O. Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Pediatr. Res. 1997, 41:599-606.
17. Fricker A.C., Mok M.H., de la Flor R., Shah A.J., Woolley M., Dawson L.A., Kew J.N. Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 2009, 56:1060-1067.
18. Gardoni F., Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur. J. Pharmacol. 2006, 545:2-10.
19. Grunze H.C., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., Greene R.W. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 1996, 16:2034-2043.
20. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11:682-696.
21. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
22. Harney S.C., Jane D.E., Anwyl R. Extrasynaptic NR2D-containing NMDARs are recruited to the synapse during LTP of NMDAR-EPSCs. J. Neurosci. 2008, 28:11685-11694.
23. Huettner J.E., Bean B.P. Block of N-methyl-d-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:1307-1311.
24. Ikonomidou C., Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol. 2002, 1:383-386.
25. Imamura Y., Ma C.L., Pabba M., Bergeron R. Sustained saturating level of glycine induces changes in NR2B-containing-NMDA receptor localization in the CA1 region of the hippocampus. J. Neurochem. 2008, 105:2454-2465.
26. Jaarsma D., Veenma-van der Duin L., Korf J. N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. J. Neurol. Sci. 1994, 127:230-233.
27. Jackson P.F., Cole D.C., Slusher B.S., Stetz S.L., Ross L.E., Donzanti B.A., Trainor D.A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J. Med. Chem. 1996, 39:619-622.
28. Kaufman A.M., Milnerwood A.J., Sepers M.D., Coquinco A., She K., Wang L., Lee H., Craig A.M., Cynader M., Raymond L.A. Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J. Neurosci. 2012, 32:3992-4003.
29. Kolodziejczyk K., Hamilton N.B., Wade A., Karadottir R., Attwell D. The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes. Brain 2009, 132:1496-1508.
30. Law A.J., Weickert C.S., Webster M.J., Herman M.M., Kleinman J.E., Harrison P.J. Expression of NMDA receptor NR1, NR2A and NR2B subunit mRNAs during development of the human hippocampal formation. Eur. J. Neurosci. 2003, 18:1197-1205.
31. Lea PMt, Wroblewska B., Sarvey J.M., Neale J.H. beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J. Neurophysiol. 2001, 85:1097-1106.
32. Li S., Jin M., Koeglsperger T., Shepardson N.E., Shankar G.M., Selkoe D.J. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 2011, 31:6627-6638.
33. Loftis J.M., Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 2003, 97:55-85.
34. Losi G., Vicini S., Neale J. NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons. Neuropharmacology 2004, 46:490-496.
35. Low C.M., Zheng F., Lyuboslavsky P., Traynelis S.F. Molecular determinants of coordinated proton and zinc inhibition of N-methyl-d-aspartate NR1/NR2A receptors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11062-11067.
36. Low C.M., Lyuboslavsky P., French A., Le P., Wyatte K., Thiel W.H., Marchan E.M., Igarashi K., Kashiwagi K., Gernert K., Williams K., Traynelis S.F., Zheng F. Molecular determinants of proton-sensitive N-methyl-d-aspartate receptor gating. Mol. Pharmacol. 2003, 63:1212-1222.
37. Lu X.M., Tang Z., Liu W., Lin Q., Slusher B.S. N-acetylaspartylglutamate protects against transient focal cerebral ischemia in rats. Eur. J. Pharmacol. 2000, 408:233-239.
38. Mony L., Kew J.N., Gunthorpe M.J., Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br. J. Pharmacol. 2009, 157:1301-1317.
39. Mony L., Krzaczkowski L., Leonetti M., Le Goff A., Alarcon K., Neyton J., Bertrand H.O., Acher F., Paoletti P. Structural basis of NR2B-selective antagonist recognition by N-methyl-d-aspartate receptors. Mol. Pharmacol. 2009, 75:60-74.
40. Mott D.D., Doherty J.J., Zhang S., Washburn M.S., Fendley M.J., Lyuboslavsky P., Traynelis S.F., Dingledine R. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat. Neurosci. 1998, 1:659-667.
41. Nagel J., Belozertseva I., Greco S., Kashkin V., Malyshkin A., Jirgensons A., Shekunova E., Eilbacher B., Bespalov A., Danysz W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology 2006, 51:1163-1171.
42. Neale J.H. N-acetylaspartylglutamate is an agonist at mGluR(3) in vivo and in vitro. J. Neurochem. 2011, 119:891-895.
43. Neale J.H., Olszewski R.T., Gehl L.M., Wroblewska B., Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci. 2005, 26:477-484.
44. Neale J.H., Olszewski R.T., Zuo D., Janczura K.J., Profaci C.P., Lavin K.M., Madore J.C., Bzdega T. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J. Neurochem. 2011, 118:490-498.
45. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Vincent Chen H.S., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
46. Orlowski P., Chappell M., Park C.S., Grau V., Payne S. Modelling of pH dynamics in brain cells after stroke. Interface Focus 2011, 1:408-416.
47. Pabba M., Wong A.Y., Ahlskog N., Hristova E., Biscaro D., Nassrallah W., Ngsee J.K., Snyder M., Beique J.C., Bergeron R. NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. J. Neurosci. 2014, 34:11325-11338.
48. Pahk A.J., Williams K. Influence of extracellular pH on inhibition by ifenprodil at N-methyl-d-aspartate receptors in Xenopus oocytes. Neurosci. Lett. 1997, 225:29-32.
49. Paoletti P., Bellone C., Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 2013, 14:383-400.
50. Parsons M.P., Raymond L.A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 2014, 82:279-293.
51. Passani L.A., Vonsattel J.P., Carter R.E., Coyle J.T. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol. Chem. Neuropathol. 1997, 31:97-118.
52. H]norepinephrine release from rat hippocampal slices. J. Pharmacol. Exp. Ther. 1993, 266:796-803.
53. Sanabria E.R., Wozniak K.M., Slusher B.S., Keller A. GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J. Neurophysiol. 2004, 91:182-193.
54. Sanz-Clemente A., Nicoll R.A., Roche K.W. Diversity in NMDA receptor composition: many regulators, many consequences. Neuroscientist 2013, 19:62-75.
55. Sekiguchi M., Okamoto K., Sakai Y. Low-concentration N-acetylaspartylglutamate suppresses the climbing fiber response of Purkinje cells in guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Res. 1989, 482:87-96.
56. Sekiguchi M., Wada K., Wenthold R.J. N-acetylaspartylglutamate acts as an agonist upon homomeric NMDA receptor (NMDAR1) expressed in Xenopus oocytes. FEBS Lett. 1992, 311:285-289.
57. Shalaby I.A., Chenard B.L., Prochniak M.A., Butler T.W. Neuroprotective effects of the N-methyl-d-aspartate receptor antagonists ifenprodil and SL-82,0715 on hippocampal cells in culture. J. Pharmacol. Exp. Ther. 1992, 260:925-932.
58. Shaywitz A.J., Greenberg M.E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 1999, 68:821-861.
59. Shipton O.A., Paulsen O. GluN2A and GluN2B subunit-containing NMDA receptors in hippocampal plasticity. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369:20130163.
60. Slusher B.S., Vornov J.J., Thomas A.G., Hurn P.D., Harukuni I., Bhardwaj A., Traystman R.J., Robinson M.B., Britton P., Lu X.C., Tortella F.C., Wozniak K.M., Yudkoff M., Potter B.M., Jackson P.F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 1999, 5:1396-1402.
61. Suarez F., Zhao Q., Monaghan D.T., Jane D.E., Jones S., Gibb A.J. Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones. Eur. J. Neurosci. 2010, 32:359-367.
62. +. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:6445-6449.
63. Tortella F.C., Lin Y., Ved H., Slusher B.S., Dave J.R. Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. Eur. J. Pharmacol. 2000, 402:31-37.
64. Tovar K.R., Westbrook G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci. 1999, 19:4180-4188.
65. Tovar K.R., McGinley M.J., Westbrook G.L. Triheteromeric NMDA receptors at hippocampal synapses. J. Neurosci. 2013, 33:9150-9160.
66. Traynelis S.F., Cull-Candy S.G. Proton inhibition of N-methyl-d-aspartate receptors in cerebellar neurons. Nature 1990, 345:347-350.
67. + sensitivity of excitatory amino acid receptor channels in rat cerebellar granule neurones. J. Physiol. 1991, 433:727-763.
68. Traynelis S.F., Hartley M., Heinemann S.F. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science 1995, 268:873-876.
69. Truelsen T., Mahonen M., Tolonen H., Asplund K., Bonita R., Vanuzzo D., Project W.M. Trends in stroke and coronary heart disease in the WHO MONICA Project. Stroke 2003, 34:1346-1352.
70. Valivullah H.M., Lancaster J., Sweetnam P.M., Neale J.H. Interactions between N-acetylaspartylglutamate and AMPA, kainate, and NMDA binding sites. J. Neurochem. 1994, 63:1714-1719.
71. van Zundert B., Yoshii A., Constantine-Paton M. Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal. Trends Neurosci. 2004, 27:428-437.
72. Vanhoutte P., Bading H. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr. Opin. Neurobiol. 2003, 13:366-371.
73. von Engelhardt J., Doganci B., Seeburg P.H., Monyer H. Synaptic NR2A- but not NR2B-containing NMDA receptors increase with blockade of ionotropic glutamate receptors. Front. Mol. Neurosci. 2009, 2:19.
74. Vyklicky L., Vlachova V., Krusek J. The effect of external pH changes on responses to excitatory amino acids in mouse hippocampal neurones. J. Physiol. 1990, 430:497-517.
75. Walder K.K., Ryan S.B., Bzdega T., Olszewski R.T., Neale J.H., Lindgren C.A. Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junction. Eur. J. Neurosci. 2013, 37:118-129.
76. Weilinger N.L., Maslieieva V., Bialecki J., Sridharan S.S., Tang P.L., Thompson R.J. Ionotropic receptors and ion channels in ischemic neuronal death and dysfunction. Acta Pharmacol. Sin. 2013, 34:39-48.
77. West A.E., Chen W.G., Dalva M.B., Dolmetsch R.E., Kornhauser J.M., Shaywitz A.J., Takasu M.A., Tao X., Greenberg M.E. Calcium regulation of neuronal gene expression. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11024-11031.
78. Westbrook G.L., Mayer M.L., Namboodiri M.A., Neale J.H. High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J. Neurosci. 1986, 6:3385-3392.
79. White B.C., Sullivan J.M., DeGracia D.J., O'Neil B.J., Neumar R.W., Grossman L.I., Rafols J.A., Krause G.S. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J. Neurol. Sci. 2000, 179:1-33.
80. Whittemore E.R., Ilyin V.I., Woodward R.M. Antagonism of N-methyl-d-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition. J. Pharmacol. Exp. Ther. 1997, 282:326-338.
81. Williams K. Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 1993, 44:851-859.
82. Wroblewska B., Wroblewski J.T., Saab O.H., Neale J.H. N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. J. Neurochem. 1993, 61:943-948.
83. Wroblewska B., Wroblewski J.T., Pshenichkin S., Surin A., Sullivan S.E., Neale J.H. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 1997, 69:174-181.
84. Wroblewska B., Santi M.R., Neale J.H. N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 1998, 24:172-179.
85. Xia P., Chen H.S., Zhang D., Lipton S.A. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 2010, 30:11246-11250.
86. Zhu S., Paoletti P. Allosteric modulators of NMDA receptors: multiple sites and mechanisms. Curr. Opin. Pharmacol. 2015, 20:14-23.